The results reported from the EMERALD-3 trial are intriguing. Several other recent immunotherapy combination trials with TACE have demonstrated similar gains in PFS compared with TACE alone in locally advanced HCC. Previously, in the EMERALD-1 trial, combination treatment with durvalumab plus bevacizumab plus TACE vs. TACE alone demonstrated a significant PFS improvement (15 months vs. 8.2 months).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Daneng Li
Immunotherapy combination may improve outcomes in unresectable liver cancer
Key takeaways: Using STRIDE with transarterial chemoembolization significantly improved PFS. Formal OS analyses have not been performed, though data suggest a trend toward improved survival. CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are not candidates for surgery, according to results of the randomized phase 3 EMERALD-3 study.
Experts examine tumor receptor expression, use of molecular imaging, and ongoing studies exploring alpha-emitting radioligand therapies and sequencing strategies in advanced NETs. To learn more, view the full series: NANETS Highlights: Updates in Clinical Development of Next-Generation Radioligand Therapies Dr Jonathan Strosberg: Welcome to our conversation.
Mechanism of Action: Beta vs Alpha Emitters
Dr Jonathan Strosberg: Welcome to our conversation. We're going to talk about ALPHAMEDIX-02 long-term data review. So ,we've been talking about lutetium-based treatments. And lutetium, of course, is a beta emitter. And maybe you want to explain what a beta emitter is, and then we can talk a little bit about how that differs from alpha emitters. So, Tom, do you want to tackle? Dr Thomas Hope: Sure. A beta emitter, lutetium, emits an electron, a beta particle, beta-negative particle.
Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?
The incidence of neuroendocrine tumors (NETs) in the US is rising, with 8.3 cases per 100,000 individuals diagnosed in 2018 compared with 6.98 cases per 100,000 individuals diagnosed in 2012.1,2 Most patients with NETs are diagnosed with metastatic disease, at which point curative surgery is no longer a treatment option.3 Prior to 2017, available treatments for advanced NETs included somatostatin analogues (lanreotide [Somatuline] and octreotide [Sandostatin]), targeted therapy (everolimus...
Liver Resection for Gastroenteropancreatic Neuroendocrine Tumors with Extrahepatic Disease
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
The relationship of mental health symptoms to chemotherapy toxicity risk in older adults with cancer: Results from the geriatric assessment-driven intervention study - Jayani - Cancer - Wiley Online Library
INTRODUCTION Mental health disorders, including depression and anxiety, are more prevalent in patients with cancer compared to the general population.1 Compared to the 5% prevalence rate of depression in the broader population of community-dwelling older adults, as many as 13% and 21% of older adults with cancer have depression and anxiety, respectively.2, 3 These mental health disorders are associated with increased health care costs in this vulnerable population, and account for 5.5% of...
Bridging healthcare disparities in the AAPI community
Back to Journals » Journal of Hepatocellular Carcinoma » Volume 11 Authors Li D , Cheng S, Wilson Woods A, Luong A , Schiltz S , Tan R, Chi ZH Received 30 April 2024 Accepted for publication 3 July 2024 Published 18 July 2024 Volume 2024:11 Pages 1439—1444 DOI https://doi.org/10.2147/JHC.S467913 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr David Gerber Daneng Li,1 Spencer Cheng,2 Andrea Wilson Woods,3 Allyson...
Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates
February 19, 2024 Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space. After the 2024 Gastrointestinal Cancers Symposium, Jun Gong, MD, and Daneng Li, MD, sat down to discuss the most relevant trial data to have come from the conference. They convened for a live X Space hosted by CancerNetwork®.
Dr Li on the Use of ADG126 With Pembrolizumab in MSS CRC
By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy
Defining MRI Superiority over CT for Colorectal and Neuroendocrine Liver Metastases
1. Introduction Colorectal cancer (CRC) and neuroendocrine tumors (NETs) are among the most common malignancies that cause liver metastasis (LM). Although the diagnosis, prognosis, and treatment options vary, surgical resection can be potentially curative in both cases. CRC is the third most common malignancy worldwide, but death rates have decreased in the United States over the last 40 years [1,2].
A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE)
Durvalumab, a PD-L1 inhibitor, is part of an immunotherapeutic drug class shown to have prolonged survival benefit in patients with advanced stage hepatocellular carcinoma (HCC). Tivozanib is a potent and selective VEGFR 1, 2 and 3 tyrosine kinase inhibitor. While these medications have both demonstrated single-agent activity in HCC and have been combined safely with other therapies, there is no data on their concurrent therapeutic effects.
Patient Preferences for Unresectable Hepatocellular Carcinoma Treatments: A Discrete-Choice Experiment
Open AccessArticle by Daneng Li 1,*, Ruoding Tan 2, Sairy Hernandez 2, Norelle Reilly 2, Cooper Bussberg 3 and Carol Mansfield 3 1 City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA 2 Genentech, Inc., South San Francisco, CA 94080, USA 3 RTI Health Solutions, Research Triangle Park, NC 27709, USA * Author to whom correspondence should be addressed.
Interpretation of the Efficacy of Multidisciplinary Geriatric Assessment Intervention on Chemotherapy-Related Toxic Effects in Older Adults With Cancer-Reply | Oncology | JAMA Oncology | JAMA Network
February 24, 2022 JAMA Oncol. 2022;8(4):1.
Lenvatinib combination improves outcomes in advanced hepatocellular carcinoma
January 27, 2022 2 min read Save Perspective from Source/Disclosures Published by: Source: Peng ZW, et al. Abstract 380. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 20-22, 2022; San Francisco. Disclosures: Peng reports no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later.
Adjuvant S-1 prolongs survival among patients with resected biliary tract cancer
January 24, 2022 2 min read Save Perspective from Source/Disclosures Published by: Source: Ikeda M, et al. Abstract 382. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan 20-22, 2022; San Francisco. Disclosures: Ikeda reports honoraria from, a consultant/advisory role with and/or institutional research funding from AstraZeneca, Bayer Yakuhin, Eisai, Eli Lilly Japan, Novartis, Takeda, Taiho Pharmaceutical and several other pharmaceutical companies.
Personalized interventions reduce chemotherapy-related toxicity among older adults
October 20, 2021 3 min read Save Source/Disclosures Published by: Disclosures: Li reports grants from AstraZeneca and Brooklyn ImmunoTherapeutics, as well as personal fees from Advanced Accelerator Applications, Bayer, Coherus BioSciences, Eisai, Exelixis, Genentech, Ipsen, Lexicon, Merck, QED Therapeutics, Sun Pharma, Taiho Pharmaceutical Co. and TerSera Therapeutics. Please see the study for all other authors’ relevant financial disclosures.
Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial
Key Points Question Can geriatric assessment–driven intervention reduce grade 3 or higher chemotherapy-related toxic effects in older adults with cancer?
Understanding the Management and Treatment of Well-Differentiated Pancreatic Neuroendocrine Tumors: A Clinician’s Guide to a Complex Illness
Pancreatic neuroendocrine tumors (PanNETs) represent a heterogeneous group of rare neoplasms that arise in the endocrine tissues of the pancreas. In general, although current nomenclature classifies PanNETs as well-differentiated tumors, the degree of tumor grade may vary widely. PanNETs are also categorized as functional (F) versus nonfunctional (NF) tumors on the basis of the presence or absence of clinical syndromes, respectively.
Study underway to evaluate novel T-cell therapy for hepatocellular carcinoma
An ongoing proof-of-concept clinical trial is underway to assess the use of a novel T-cell therapy for the treatment of advanced hepatocellular carcinoma. “Traditional immunotherapy, such as checkpoint inhibitors, releases the brakes on the immune system, which allows it to attack the tumor but can also lead to attacks on other parts of the human body,” Daneng Li, MD, medical oncologist at City of Hope, said in a press release.
Patient-defined goals and preferences among older adults with cancer starting chemotherapy (CT).
10009 Background: Older adults with cancer facing decisions with competing health outcomes may favor maintaining quality of life (QOL), independence, or cognition over prolonging survival. The goal of this study was to elicit preferences among outcomes from older adults starting CT. Methods: This is a secondary analysis of an ongoing prospective study aimed at identifying and addressing vulnerabilities in older adults (age ≥65) starting CT (NCT02517034).
Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer
Gut dysbiosis: a potential link between increased cancer risk in ageing and inflammaging
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Daneng
Contact Daneng, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack